| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| SHERMAN JEFFREY W | Director | C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO | /s/ Beth Hecht, Attorney-in-Fact | 04 Jun 2025 | 0001230482 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | XERS | Common Stock | Award | $0 | +50,000 | +30% | $0.000000 | 214,380 | 04 Jun 2025 | Direct | F1 |
| holding | XERS | Common Stock | 5,400 | 04 Jun 2025 | By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001 | F2 |
| Id | Content |
|---|---|
| F1 | These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders. |
| F2 | The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |